Glycyrrhizin
CAS 1405-86-3
Glycyrrhizin (CAS 1405-86-3) is a Phase 2 pharmaceutical compound with 4 bioactivity targets and 102 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 26431.200689655172 nM | 28 | - |
| - | EC50 | 13359.857142857143 nM | 7 | - |
| - | Ki | 7450 nM | 5 | - |
| - | Potency | 17392.55 nM | 2 | - |
| - | EC50 | 0.44 ug.mL-1 | 1 | - |
| - | IC50 | 572 molar ratio | 1 | - |
| - | Kd | 87000 nM | 1 | - |
| Corticosteroid 11-beta-dehydrogenase isozyme 2 Enzyme |
IC50 | 9.4 | - | Homo sapiens |
| Corticosteroid 11-beta-dehydrogenase isozyme 1 Enzyme |
IC50 | 8.22 | - | Homo sapiens |
| Beta-glucuronidase Enzyme |
IC50 | 4.01 | - | Rattus norvegicus |
| Corticosteroid 11-beta-dehydrogenase isozyme 1 Enzyme |
IC50 | 8.52 | - | Mus musculus |
| High mobility group protein B1 Nuclear other |
Kd | 4.06 | - | Homo sapiens |
| Beta-glucuronidase Enzyme |
IC50 | 4.92 | - | Escherichia coli |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Hepatic function abnormal | 19 | 63.222 | 10019670 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| OATP1B1 SLCO1B1 |
Inhibition | - | - |
| OATP1B3 SLCO1B3 |
Inhibition | - | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| GLYCYRRHIZIN | 26143 | SU | MTHSPL |
| glycyrrhizin | 26143 | SY | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Glycyrrhizin used for in pharmaceutical contexts?
Glycyrrhizin (CAS 1405-86-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Glycyrrhizin?
Glycyrrhizin has 102 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Hepatic function abnormal, Cytomegalovirus infection, Graft versus host disease in lung, Pneumonia staphylococcal, Staphylococcal bacteraemia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Glycyrrhizin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Glycyrrhizic Acid with EU status "restricted".
What clinical phase is Glycyrrhizin in?
Glycyrrhizin is rendered with ChEMBL max phase 2.
What bioactivity targets are documented for Glycyrrhizin?
Glycyrrhizin has 13 bioactivity rows in this page query. Rendered target entries include Corticosteroid 11-beta-dehydrogenase isozyme 2, Corticosteroid 11-beta-dehydrogenase isozyme 1, Beta-glucuronidase, High mobility group protein B1.